Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 11:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,014 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Adult Volunteers Clear all

Conditions: Healthy
Interventions: K-877, Clopidogrel; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Anaemia
Interventions: Daprodustat; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 259 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Anaheim, California • Overland Park, Kansas • Las Vegas, Nevada + 1 more

Conditions: Molybdenum Cofactor Deficiency (MoCD), Rare Autosomal Recessive Disorder, Deficiency of Activity of Molybdenum-dependent Enzymes (Sulfite Oxidase [SOX], Xanthine Dehydrogenase, and Aldehyde Oxidase)
Interventions: ALXN1101, Placebo; Drug
Lead sponsor: Origin Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Osteogenesis Imperfecta
Interventions: AGA2115, Placebo; Drug
Lead sponsor: Angitia Incorporated Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Lake Forest, California

Conditions: Healthy Adult Volunteers
Interventions: NB-1008, Control; Biological · Other
Lead sponsor: NanoBio Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 199 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy Subjects, Pharmacokinetics of Isavuconazole, Pharmacokinetics of Prednisolone
Interventions: Isavuconazole, Prednisone; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Volunteers
Interventions: ETI-204, "Anthim", placebo; Drug · Other
Lead sponsor: Elusys Therapeutics; Other
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy Volunteers
Interventions: ABBV-552; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: Anaheim, California • Las Vegas, Nevada

Conditions: Shigellosis, Bacillary Dysentery
Interventions: Shigella flexneri 2a InvaplexAR; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Healthy Volunteers
Interventions: BPT, NP; Other
Lead sponsor: Lumos Labs, Inc.; Industry
Eligibility: 70 Years to 89 Years
Enrollment: 229 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Garden Grove, California • Oakland, California • Torrance, California

Conditions: Healthy
Interventions: SRX246, Placebo; Drug
Lead sponsor: Azevan Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Obesity, Overweight, Healthy
Interventions: PF-04620110, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy, HIV Infections
Interventions: VRC-HIVADV014-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 44 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Duchenne Muscular Dystrophy, Exon 44
Interventions: AOC 1044, Placebo; Drug
Lead sponsor: Avidity Biosciences, Inc.; Industry
Eligibility: 7 Years to 55 Years · Male only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Little Rock, Arkansas • La Jolla, California • Palo Alto, California + 7 more

Conditions: Skin and Soft Tissue Infections, Methicillin-resistant Staphylococcus Aureus
Interventions: EDP-322; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers
Interventions: Efprezimod alfa, Saline; Biological · Drug
Lead sponsor: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD)
Interventions: ABBV-932, Placebo for ABBV-932; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Los Alamitos, California • Grayslake, Illinois • Marlton, New Jersey

Conditions: Healthy
Interventions: SPD503, Concerta, SPD503 + Concerta; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Healthy Adult Male and Female Volunteers
Interventions: AVP-923; Drug
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Psilocybin; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: ITCA 650 20/60 mcg/day, Acetaminophen, Atorvastatin, Lisinopril, Warfarin, Digoxin; Drug
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Plague
Interventions: Flagellin/F1/V, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy Volunteers
Interventions: ABBV-668 IR, ABBV-668 ER; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Healthy Volunteer Study
Interventions: AT-527 (R07496998); Drug
Lead sponsor: Atea Pharmaceuticals, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Search by objective public record fields.

Drug-Drug Interaction Study to Assess the Effects of Multi Dose Clopidogrel on the Pharmacokinetics of Single-Dose K-877 in Healthy Adult Volunteers

Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Participants

Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers

A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers

Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008

A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Prednisone in Healthy Adult Subjects

Intravenous Dose-Escalation Study With ETI-204 in Adult Volunteers

A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants

Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)

Validity of an Online Neurocognitive Test Battery, the Brain Performance Test (BPT), in Normal Healthy Adults

Study of SRX246 Capsules in Healthy Adult Volunteers

A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

Safety and Immunogenicity of an HIV Vaccine in Normal Adult Volunteers

Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping

Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers

Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers

Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants

UW Psilocybin Pharmacokinetics Study

Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs

Dose Escalation Trial of a Plague Vaccine, Flagellin/F1/V, in Healthy Adult Volunteers

A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants

Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)